At the end of the latest market close, Arrowhead Pharmaceuticals Inc. (ARWR) was valued at $83.72. In that particular session, Stock kicked-off at the price of $81.70 while reaching the peak value of $84.41 and lowest value recorded on the day was $80.80. The stock current value is $86.41.
Recently in News on June 3, 2021, Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia. Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG). Arrowhead also intends to initiate a Phase 2b study and a Phase 3 study of ARO-APOC3 in two additional patient populations in 2021. You can read further details here
Arrowhead Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $92.60 on 02/10/21, with the lowest value was $60.52 for the same time period, recorded on 04/12/21.
Arrowhead Pharmaceuticals Inc. (ARWR) full year performance was 139.13%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Arrowhead Pharmaceuticals Inc. shares are logging -6.68% during the 52-week period from high price, and 180.28% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $30.83 and $92.60.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 708284 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Arrowhead Pharmaceuticals Inc. (ARWR) recorded performance in the market was 9.11%, having the revenues showcasing 14.40% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.30B, as it employees total of 98 workers.
Arrowhead Pharmaceuticals Inc. (ARWR) in the eye of market guru’s
During the last month, 9 analysts gave the Arrowhead Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 74.22, with a change in the price was noted +5.06. In a similar fashion, Arrowhead Pharmaceuticals Inc. posted a movement of +6.16% for the period of last 100 days, recording 761,506 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ARWR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Arrowhead Pharmaceuticals Inc. (ARWR): Stocks Technical analysis and Trends
Raw Stochastic average of Arrowhead Pharmaceuticals Inc. in the period of last 50 days is set at 88.61%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 84.85%. In the last 20 days, the company’s Stochastic %K was 91.64% and its Stochastic %D was recorded 94.02%.
If we look into the earlier routines of Arrowhead Pharmaceuticals Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 9.11%. Additionally, trading for the stock in the period of the last six months notably improved by 22.79%, alongside a boost of 139.13% for the period of the last 12 months. The shares increased approximately by 15.44% in the 7-day charts and went down by 19.93% in the period of the last 30 days. Common stock shares were driven by 14.40% during last recorded quarter.